Complications and treatment of the myelodysplastic syndromes

Tricot, Guido

doi:10.1016/0145-2126(92)90110-s

Cited by 5 publications

(2 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The therapeutic goal in low risk patients is to increase the hemoglobin, neutrophil and platelet counts in order to decrease transfusion needs and to avoid the incidence of bleeding or infections. In the high risk group the objective is to eliminate the abnormal clone (12,26) .…”

Section: Introductionmentioning

confidence: 99%

Does soy increase blood counts in myelodysplastic syndromes?

Viana¹,

Claricia²,

Pinheiro³

et al. 2010

J. Bras. Patol. Med. Lab.

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Does soy increase blood counts in myelodysplastic syndromes?

Viana¹,

Claricia²,

Pinheiro³

et al. 2010

J. Bras. Patol. Med. Lab.

View full text Add to dashboard Cite

show abstract

“…In addition to FAB subtyping, analysis of the percentage of blasts, degrees of cytopenias, and chromosomal studies have resulted in a widely accepted prognostic scoring system (IPSS) [5,6]. These differences provide some guidelines for the management of MDS patients which generally consists of supportive measures for the low-risk group and cytostatic therapy for the high-risk group [7][8][9].…”

Section: Introductionmentioning

confidence: 99%

Phase II study of combination human recombinant GM-CSF with intermediate-dose cytarabine and mitoxantrone chemotherapy in patients with high-risk myelodysplastic syndromes (RAEB, RAEBT, and CMML): An Eastern Cooperative Oncology Group Study

et al. 2000

View full text Add to dashboard Cite

A Phase II study of GM-CSF with intermediate-dose cytarabine and mitoxantrone was conducted in patients with high-risk myelodysplastic syndrome. It was designed to evaluate if priming with growth factor could increase the efficiency of chemotherapy. In this older population only two of 10 patients achieved a bone marrow CR, including one patient whose leukemic blasts had an "S" phase increase of 2.55× at 48 hr. Unexpected hepatotoxicity was noted. This regimen cannot be recommended for this elderly population of patients. Am.

show abstract

Recent-onset myelodysplastic syndrome mimicking acute leukemia during infection

Friedman

Landaw²

1996

Ann Hematol

View full text Add to dashboard Cite

A previously healthy 74-year-old patient without a prior history of hematological disease presented with an acute respiratory infection. Peripheral pancytopenia led us to perform a bone marrow biopsy, and the diagnosis of undifferentiated acute myelogenous leukemia (AML, 61% blasts) was made. Following antibiotic treatment and resolution of the infection, the blast count in the bone marrow fell to 2%, leaving a clinicopathologic picture consistent with myelodysplastic syndrome (MDS, French-American-British type refractory anemia), and the patient survived for a total of 16.5 months following the initial presentation with cytokine support. A preterminal blast proliferation occurred during a bacterial ear infection and rapidly responded to a withdrawal of cytokine support, antibiotic therapy, and hydroxyurea. The patient succumbed ultimately to an apparent myocardial infarct. Clinicians should consider transient acceleration of MDS in their differential diagnosis when confronted with apparent AML and acute infection.

show abstract

Complications and treatment of the myelodysplastic syndromes

Cited by 5 publications

References 44 publications

Does soy increase blood counts in myelodysplastic syndromes?

Does soy increase blood counts in myelodysplastic syndromes?

Phase II study of combination human recombinant GM-CSF with intermediate-dose cytarabine and mitoxantrone chemotherapy in patients with high-risk myelodysplastic syndromes (RAEB, RAEBT, and CMML): An Eastern Cooperative Oncology Group Study

Recent-onset myelodysplastic syndrome mimicking acute leukemia during infection

Contact Info

Product

Resources

About